Cytotoxicity of 15-deoxy-Δ12,14-prostaglandin J2 through ppar£γ-independent pathway and the involvement of the JNK and AKT pathway in renal cell carcinoma

International Journal of Medical Sciences

Volumn 9, Issue 7, 2012, Pages 555-566

  Fujita, Megumi ^a   Tohji, Chiaki ^a   Honda, Yoko ^a   Yamamoto, Yasuhiro ^b   Nakamura, Tsutomu ^b   Yagami, Tatsurou ^b   Yamamori, Motohiro ^a   Okamura, Noboru ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

15 deoxy 12,14supprostaglandin J2; AKT; Apoptosis; JNK MAPK; Ppar ; Renal cell carcinoma

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; ALPHA TOCOPHEROL; ANTIOXIDANT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; FLUORESCENT DYE; HOE 33342; LACTATE DEHYDROGENASE; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRIGHTFIELD FLUORESCENT MICROSCOPE; CANCER CELL CULTURE; CELL VIABILITY; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MICROSCOPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

ANTIOXIDANTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLUOROMETRY; HUMANS; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; MAP KINASE KINASE 4; MICROSCOPY, FLUORESCENCE; PPAR GAMMA; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES;

EID: 84866561543     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.4455     Document Type: Article

References (40)

1. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006; 33:527-533.
2. Amato RJ. Renal cell carcinoma. Review of novel single agent therapeu-tics and combination regimens. Ann Oncol 2005; 16:7-15.
3. Pirrotta MT, Bernardeschi P, Fiorentini G. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 2011; 18:1651-1657.
4. Flaherty KT, Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol 2010; 80:638-646.
5. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcino-ma. Clin Cancer Res 2010; 16:3628-3638.
6. Fujita M, Yagami T, Fujio M, Tohji C, Takase K, Yamamoto Y, Sawada K, Yamamori M, Okamura N. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell car-cinoma. Cancer Lett 2011; 312:219-227.
7. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
8. Camp HS, Ren D, Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med 2002; 8:442-447.
9. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004; 25:331-336.
10. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277:23534-23543.
11. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003; 9:1-9.
12. York M, Abdelrahim M, Chintharlapall S, Lucero SD, Safe S. 1,1-Bis(3'-Indolyl)-1-(p-Substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin Cancer Res 2007; 13:6743-6752.
13. von Schwarzenberg K, Held SA, Schaub A, Brauer KM, Bringmann A, Brossart P. Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone. Cell Mol Life Sci 2009; 66:1295-1308.
14. 2 as a potential endog-enous regulator of redox-sensitive transcription factors. Biochem Phar-macol 2006; 72:1516-1528.
15. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83:813-819.
16. 2 in human breast cancer and metastasis. Int J Cancer 2003; 103:84-90.
17. 2 in colon carcinoma cells: evi-dence for a redox-sensitive peroxisome proliferator-activated recep-tor-γ-independent mechanism. Cancer Res 2004; 64:5162-5171.
18. Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, Park JI. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 2009; 15:5414-5425.
19. Schaefer, KL Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A, Saubermann LJ. PPARγ inhibitors reduce tubulin protein levels by a PPARγ, PPARδ and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colo-rectal carcinoma cells. Int J Cancer 2006; 120:702-713.
20. Allred CD, Kilgore MW. Selective activation of PPARγ in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 2005; 235:21-29.
21. 2-induced apoptosis does not require PPARγ in breast cancer cells. J Lipid Res 2002; 43:1818-1828.
22. 2 regulates apoptosis induction and nuclear factor-κB activation via a peroxisome proliferator-activated recep-tor-γ-independent mechanism in hepatocellular carcinoma. Lab Invest 2003; 83:1529-1539.
23. Yuan J, Takahashi A, Masumori N, Itoh N, Tsukamoto T. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma. Int J Urol 2006; 13:265-270.
24. Yuan J, Takahashi A, Masumori N, Uchida K, Hisasue S, Kitamura H, Itoh N, Tsukamoto T. Ligand for peroxisome proliferator-activated re-ceptor gamma have potent antitumor effect against human renal cell carcinoma. Urology 2005; 65:594-599.
25. Yoshimura R, Matsuyama M, Hase T, Tsuchida K, Kuratsukuri K, Ka-wahito Y, Sano H, Segawa Y, Nakatani T. The effect of peroxisome pro-liferator-activated receptor-γ ligand on urological cancer cells. Int J Mol Med 2003; 12:861-865.
26. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARγ-independent induction of growth arrest and apoptosis in pros-tate and bladder carcinoma. BMC Cancer 2006; 6:53.
27. 2 inhib-its neuroblastoma cell growth through induction of apoptosis: associa-tion with extracellular signal-regulated kinase signal pathway. J Phar-macol Exp Ther 2003; 307:505-517.
28. 2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001; 276:38152-38158.
29. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 2002; 277:29681-29685.
30. 2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem Biophys Res Commun 2005; 328:375-382.
31. 2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. J Biol Chem 2008; 283:30273-30288.
32. 2: the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A 2002; 99:7367-7372.
33. 2 induces renal epithelial cell death through NF-κB-dependent and MAPK-independent mechanism. Toxicol Appl Pharmacol 2006; 216:426-435.
34. 2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways. Biochem Biophys Res Commun 2011; 410:563-567.
35. Kim YM, Chung HT, Simmons RL, Billiar TR. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 2000; 275:10954-10961.
36. Atarod EB, Kehrer JP. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radic Biol Med 2004; 37:36-47.
37. Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, Inoue H. Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ. Br J Cancer 2002; 86:1303-1309.
38. 2, a ligand for peroxisome prolifera-tor-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 1999; 262:579-585.
39. 2 in MCF7 breast cancer cells. Biochemistry 2003; 42:5429-5437.
40. Na HK, Surh YJ. Peroxisome proliferator-activated receptor γ (PPARγ) ligands as bifunctional regulators of cell proliferation. Biochem Phar-macol 2003; 66:1381-1391.